Trial reportAmerican journal of hematology2020
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.
2 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in American journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 88 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
12.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Primary Immune Thrombocytopenia
Marker Expression in Pediatric Patients With Immune Thrombocytopenic Purpura Receiving Second Line Therapy
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 176 citations in OpenAlex.
- Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis.Annals of hematology · 2022Pooled it
- Impact of Batoclimab Treatment on LDL-C with and Without Coadministration of Atorvastatin: Results from a Phase I Randomized Study in Healthy Participants.Drug safety · 2025Trial
- ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis.Annals of clinical and translational neurology · 2025Trial
- Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants.Drugs in R&D · 2024Trial
- FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.Frontiers in immunology · 2022Trial
- Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.Blood advances · 2020Trial
- Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.American journal of hematology · 2020Trial
- FcRn-Targeted Alpha Therapy Using [Molecular imaging and biology · 2026Article
- In-Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis.Annals of clinical and translational neurology · 2026Article
- Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.EClinicalMedicine · 2026Article
- Rapid neurological recovery in Guillain-Barré syndrome treated with efgartigimod.Scientific reports · 2026Article
- Immune thrombocytopenia in patients with connective tissue disease.Clinical rheumatology · 2026Review
- A Clinician Perspective for a Personalized Approach to Management of Chronic Immune Thrombocytopenia with Targeted Therapies Alone or in Combination.Journal of clinical medicine · 2026Review
- Translational immunothrombosis in autoimmune Heparin-Induced thrombocytopenia: targeting the FcγRIIa-Syk-BTK and complement pathways.Clinical and experimental medicine · 2026Review
- Autoantibodies as Precision Tools in Connective Tissue Diseases: From Epiphenomenon to Endophenotype.Antibodies (Basel, Switzerland) · 2026Review
- Limitations of rituximab in treating primary immune thrombocytopenia and the therapeutic potentials of alternatives.Current opinion in hematology · 2026Review
- Efficacy, Safety, and Tolerability of Subcutaneous Efgartigimod PH20 in Chinese Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Prespecified Subpopulation Analysis of the Multicentre, Randomised-Withdrawal, Double-Blind, Placebo-Controlled, Phase II ADHERE Trial.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Thrombocytopenia: from physiological homeostasis imbalance to mechanism-driven precision diagnosis and therapy.Frontiers in immunology · 2026Review
- Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications.Biomedicines · 2025Review
- Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination models.Human vaccines & immunotherapeutics · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 7 countries.
Adrian C NewlandDepartment of Haematology, Centre for Haematology, The Royal London Hospital, London, UK.
Blanca Sánchez-GonzálezDepartment of Hematology, Hospital del Mar, Barcelona, Spain.
László RejtőDepartment of Hematology, Jósa András Teaching Hospital, Nyíregyháza, Hungary.
Miklos EgyedDepartment of Hematology, Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
Nataliya RomanyukMykolaiv Regional Clinical Hospital, Mykolaiv, Ukraine.
Marie Godarargenx BVBA, Industriepark-Zwijnaarde 7, Zwijnaarde, Belgium.ORCID 0000-0002-5477-7726
Katrien Verschuerenargenx BVBA, Industriepark-Zwijnaarde 7, Zwijnaarde, Belgium.
Domenica Gandiniargenx BVBA, Industriepark-Zwijnaarde 7, Zwijnaarde, Belgium.
Peter Ulrichtsargenx BVBA, Industriepark-Zwijnaarde 7, Zwijnaarde, Belgium.
Jon Beauchampargenx BVBA, Industriepark-Zwijnaarde 7, Zwijnaarde, Belgium.
Torsten Dreierargenx BVBA, Industriepark-Zwijnaarde 7, Zwijnaarde, Belgium.
E Sally WardDepartment of Molecular and Cellular Medicine, Texas A&M University Health Science Center, College Station, Texas.ORCID 0000-0003-3232-7238
Marc MichelService de Médecine Interne, Centre National de Référence des Cytopénies Auto-Immunes de l'Adulte, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France.
Howard A LiebmanJane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California, Los Angeles, California.
Hans de Haardargenx BVBA, Industriepark-Zwijnaarde 7, Zwijnaarde, Belgium.ORCID 0000-0001-8707-0084
Nicolas Leupinargenx BVBA, Industriepark-Zwijnaarde 7, Zwijnaarde, Belgium.
David J KuterDepartment of Hematology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-7855-2409
Ablynx (Belgium) · BEAdmiral Makarov National University of Shipbuilding · UAHarvard University · USHospital Del Mar · ESJósa András Múzeum · HURoyal London Hospital · GBSomogy Megyei Kaposi Mór Oktató Kórház · HUTexas A&M Health Science Center · USUniversité Paris-Est Créteil · FRUniversity of Southern California · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder, characterized by a low platelet count (<100 × 10
Indexed as
Purpura, Thrombocytopenic, IdiopathicAdultAgedDouble-Blind MethodFemaleFollow-Up StudiesHistocompatibility Antigens Class IHumansImmunoglobulin Fc FragmentsImmunoglobulin GMaleMiddle AgedPlatelet CountReceptors, FcFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin Fc FragmentsImmunoglobulin GReceptors, Fc
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT03102593ClinicalTrials.gov
NCT06093529ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.